Tenaya Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $156.4M
- Price
- $0.6973
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.98%
- Volume
- 1.2M
About
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding224.2M
Computed float115.7M
Float / shares51.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001858848
AI Summary
AI-generated1/28
standardmixedearnings
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics reported Q2 2026 net loss of $43.4 million, or $0.20 per share, driven by a $21.8 million non-cash impairment charge related to the early termination of its manufacturing facility lease.
The company ended the quarter with $78.1 million in cash, which it expects to fund operations into Q3 2027, supported by a $10 million upfront payment from a collaboration with Alnylam.
Positive interim data were reported from the MyPEAK-1 and RIDGE-1 trials for TN-201 and TN-401, with additional data and regulatory updates expected in Q4 2026.
Eric Hyllengren was appointed Chief Financial Officer, effective July 13, 2026.
Red flags
- Net loss widened year-over-year due to a $21.8 million impairment charge
- Company decommissioned its Genetic Medicines Manufacturing Center as part of cost reduction efforts